Harvard
Andreassen, M, Faber, J, Vestergaard, H, Kistorp, C & Kristensen, LØ 2007, '
N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances'
Clinical Endocrinology, bind 66, nr. 5, s. 619-25.
https://doi.org/10.1111/j.1365-2265.2007.02782.x
APA
Andreassen, M., Faber, J., Vestergaard, H., Kistorp, C., & Kristensen, L. Ø. (2007).
N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances.
Clinical Endocrinology,
66(5), 619-25.
https://doi.org/10.1111/j.1365-2265.2007.02782.x
CBE
MLA
Vancouver
Author
Bibtex
@article{16f29b1942974822ba9b8d4622e2317a,
title = "N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances",
abstract = "BACKGROUND: Acromegaly is associated with hypertrophic cardiomyopathy, hypertension and subsequent congestive heart failure. Impairment of cardiac function has also been associated with growth hormone deficiency (GHD). B-type natriuretic peptides (BNPs) have emerged as strong diagnostic and prognostic risk markers. They are cardioprotective hormones that compensate heart disease by promoting natriuresis and modulation of cardiac hypertrophy in response to volume expansion and ventricular wall stretch.OBJECTIVE: To investigate N-terminal pro-BNP (NT-proBNP) in patients with GH disturbances before and after treatment, and in healthy gender- and age-matched controls.SUBJECTS AND METHODS: Ten acromegalic patients (age 48 +/- 12 years) and 10 patients with GHD (age 41 +/- 14 years) were studied. None had symptoms or signs of cardiovascular disease except for hypertension. Serum NT-proBNP was measured before and 3, 6, 12 and 24 months after treatment.RESULTS: Baseline NT-proBNP was lower in acromegalic patients [median (interquartile range) 24.3 (17.8-33.0) pg/ml] than in 20 healthy matched controls [57.9 (35.4-92.2) pg/ml; P < 0.001]. NT-proBNP increased during treatment (P = 0.002), concomitant with a decrease in IGF-I (P < 0.001). After 3 months of treatment NT-proBNP peaked, with a fourfold increase to 96.4 (57.8-113.2) pg/ml. NT-proBNP did not differ in patients with GHD compared with controls (P = 0.19), and did not change during treatment (P = 0.39).CONCLUSION: Untreated patients with acromegaly had low NT-proBNP levels that increased fourfold after treatment. This is in contrast to other conditions with cardiac hypertrophy. Further studies are required to determine the significance of this novel finding in relation to acromegalic cardiac disease.",
keywords = "Acromegaly, Adult, Aged, Analysis of Variance, Antineoplastic Agents, Hormonal, Biomarkers, Case-Control Studies, Female, Follow-Up Studies, Growth Hormone, Humans, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I, Male, Middle Aged, Natriuretic Peptide, Brain, Octreotide, Peptide Fragments, Peptides, Cyclic, Protein Precursors, Retrospective Studies, Somatostatin, Statistics, Nonparametric, Journal Article",
author = "Mikkel Andreassen and Jens Faber and Henrik Vestergaard and Caroline Kistorp and Kristensen, {Lars {\O}stergaard}",
year = "2007",
month = "5",
doi = "10.1111/j.1365-2265.2007.02782.x",
language = "English",
volume = "66",
pages = "619--25",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",
}
RIS
TY - JOUR
T1 - N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances
AU - Andreassen, Mikkel
AU - Faber, Jens
AU - Vestergaard, Henrik
AU - Kistorp, Caroline
AU - Kristensen, Lars Østergaard
PY - 2007/5
Y1 - 2007/5
N2 - BACKGROUND: Acromegaly is associated with hypertrophic cardiomyopathy, hypertension and subsequent congestive heart failure. Impairment of cardiac function has also been associated with growth hormone deficiency (GHD). B-type natriuretic peptides (BNPs) have emerged as strong diagnostic and prognostic risk markers. They are cardioprotective hormones that compensate heart disease by promoting natriuresis and modulation of cardiac hypertrophy in response to volume expansion and ventricular wall stretch.OBJECTIVE: To investigate N-terminal pro-BNP (NT-proBNP) in patients with GH disturbances before and after treatment, and in healthy gender- and age-matched controls.SUBJECTS AND METHODS: Ten acromegalic patients (age 48 +/- 12 years) and 10 patients with GHD (age 41 +/- 14 years) were studied. None had symptoms or signs of cardiovascular disease except for hypertension. Serum NT-proBNP was measured before and 3, 6, 12 and 24 months after treatment.RESULTS: Baseline NT-proBNP was lower in acromegalic patients [median (interquartile range) 24.3 (17.8-33.0) pg/ml] than in 20 healthy matched controls [57.9 (35.4-92.2) pg/ml; P < 0.001]. NT-proBNP increased during treatment (P = 0.002), concomitant with a decrease in IGF-I (P < 0.001). After 3 months of treatment NT-proBNP peaked, with a fourfold increase to 96.4 (57.8-113.2) pg/ml. NT-proBNP did not differ in patients with GHD compared with controls (P = 0.19), and did not change during treatment (P = 0.39).CONCLUSION: Untreated patients with acromegaly had low NT-proBNP levels that increased fourfold after treatment. This is in contrast to other conditions with cardiac hypertrophy. Further studies are required to determine the significance of this novel finding in relation to acromegalic cardiac disease.
AB - BACKGROUND: Acromegaly is associated with hypertrophic cardiomyopathy, hypertension and subsequent congestive heart failure. Impairment of cardiac function has also been associated with growth hormone deficiency (GHD). B-type natriuretic peptides (BNPs) have emerged as strong diagnostic and prognostic risk markers. They are cardioprotective hormones that compensate heart disease by promoting natriuresis and modulation of cardiac hypertrophy in response to volume expansion and ventricular wall stretch.OBJECTIVE: To investigate N-terminal pro-BNP (NT-proBNP) in patients with GH disturbances before and after treatment, and in healthy gender- and age-matched controls.SUBJECTS AND METHODS: Ten acromegalic patients (age 48 +/- 12 years) and 10 patients with GHD (age 41 +/- 14 years) were studied. None had symptoms or signs of cardiovascular disease except for hypertension. Serum NT-proBNP was measured before and 3, 6, 12 and 24 months after treatment.RESULTS: Baseline NT-proBNP was lower in acromegalic patients [median (interquartile range) 24.3 (17.8-33.0) pg/ml] than in 20 healthy matched controls [57.9 (35.4-92.2) pg/ml; P < 0.001]. NT-proBNP increased during treatment (P = 0.002), concomitant with a decrease in IGF-I (P < 0.001). After 3 months of treatment NT-proBNP peaked, with a fourfold increase to 96.4 (57.8-113.2) pg/ml. NT-proBNP did not differ in patients with GHD compared with controls (P = 0.19), and did not change during treatment (P = 0.39).CONCLUSION: Untreated patients with acromegaly had low NT-proBNP levels that increased fourfold after treatment. This is in contrast to other conditions with cardiac hypertrophy. Further studies are required to determine the significance of this novel finding in relation to acromegalic cardiac disease.
KW - Acromegaly
KW - Adult
KW - Aged
KW - Analysis of Variance
KW - Antineoplastic Agents, Hormonal
KW - Biomarkers
KW - Case-Control Studies
KW - Female
KW - Follow-Up Studies
KW - Growth Hormone
KW - Humans
KW - Insulin-Like Growth Factor Binding Protein 3
KW - Insulin-Like Growth Factor I
KW - Male
KW - Middle Aged
KW - Natriuretic Peptide, Brain
KW - Octreotide
KW - Peptide Fragments
KW - Peptides, Cyclic
KW - Protein Precursors
KW - Retrospective Studies
KW - Somatostatin
KW - Statistics, Nonparametric
KW - Journal Article
U2 - 10.1111/j.1365-2265.2007.02782.x
DO - 10.1111/j.1365-2265.2007.02782.x
M3 - Journal article
VL - 66
SP - 619
EP - 625
JO - Clinical Endocrinology
JF - Clinical Endocrinology
SN - 0300-0664
IS - 5
ER -